IMPORTANCE Schizophrenia is associated with an increased risk of type 2 diabetes. However, it is not clear whether schizophrenia confers an inherent risk for glucose dysregulation in the absence of the effects of chronic illness and long-term treatment.
L arge-scale epidemiologic studies have established that people with schizophrenia die 15 to 30 years earlier than the general population and that 60% or more of this premature mortality is due to causes not related to the central nervous system, [1] [2] [3] [4] [5] predominantly cardiovascular. 6 Rates of type 2 diabetes are estimated to be 2 to 3 times higher in schizophrenia than in the general population, with a prevalence of 10% to 15%. 7, 8 Although antipsychotic use may contribute to this association, a link between schizophrenia and diabetes was already observed in the 19th century, long before the introduction of antipsychotics and in an era when diets did not have such a propensity to induce metabolic derangements. 9, 10 For over a decade, there has been a drive to identify whether schizophrenia confers an inherent risk for the development of type 2 diabetes by investigating patients at illness onset before the potentially confounding effects of chronic illness and long-term antipsychotic treatment. Several studies have focused on the presence or absence of type 2 diabetes in patient cohorts compared with controls. The results from metaanalyses of these studies examining the prevalence of type 2 diabetes in individuals with first-episode psychosis and controls have found no significant differences between the 2 groups. 11, 12 However, there are 2 limitations with restricting analyses to an established diagnosis of type 2 diabetes. The first limitation is that patients may be less likely to seek medical attention, so there is the risk of underreporting. The second is that the development of type 2 diabetes takes time, with peak onset in middle age, and so may not have had time to develop in patients with first-episode schizophrenia. Type 2 diabetes shows a progression through a period of insulin resistance, elevated insulin levels, and impaired glucose tolerance (prediabetes) before the development of symptoms and a patient eventually receiving a diagnosis of type 2 diabetes. If a study's outcome is whether criteria are met for a diagnosis of type 2 diabetes, significant alterations in glucose homeostasis between patient and control groups may be missed. In view of these limitations, we performed a meta-analysis of studies that focused on measures of glucose control in individuals either at risk for psychosis or in their first episode of psychosis. The aim of our meta-analysis was to test the hypothesis that individuals with first-episode schizophrenia exhibit alterations in glucose homeostasis compared with matched controls.
Methods

Selection Procedures
A systematic review was performed according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) 13 and MOOSE (Meta-analysis of Observational Studies in Epidemiology) 14 guidelines (eTables 1 and 2 in the Supplement). Two of us (T.P. and K.B.) independently searched MEDLINE (from 1946 to week 2 of April 2016), EMBASE (from 1947 to April 25, 2016) , and PsycINFO (from 1806 to week 2 of April 2016). The following key words were used: (schizophrenia or schizoaffective or psychosis or psychotic) and (early onset or first episode or at risk or ultra high risk or prodrome) and (medication or drug or antipsychotic) and (glucose or diabetes or type 2 or prediabetes or intolerance or oral glucose tolerance test or OGTT)orfasting or random or insulin or insulin resistance or hemoglobin [Hb] A 1c or homeosta* or homeostatic model assessment of insulin resistance [HOMA-IR]). Studies in any language were considered, although all the included articles were published in English. The search was complemented by hand-searching of meta-analyses and review articles. Abstracts were screened and the full texts of relevant studies were retrieved. If full texts or abstracts were not available, authors were contacted and articles requested. Two of us (T.P. and K.B.) selected the final studies for review and meta-analysis.
Selection Criteria
Inclusion criteria were (1) a DSM or International Statistical Classification of Diseases and Related Health Problems diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, schizophrenia spectrum or psychotic disorder not otherwise specified, or an at-risk mental state for psychosis according to research criteria 15, 16 ; (2) first episode of illness (defined either as first treatment contact [inpatient or outpatient] or duration of illness up to 5 years following illness onset 17 ); (3) antipsychotic naive or minimal exposure (≤2 weeks of antipsychotic treatment); (4) a healthy control group; (5) glucose homeostasis assessment including 1 or more fasting plasma glucose concentration, random plasma glucose concentration, oral glucose tolerance test (OGTT), percentage of hemoglobin A1 that is glycated (HbA 1c ), or insulin resistance as measured using the homeostatic model assessment (HOMA). The OGTT was required to meet the American Diabetes Association (ADA) 18 and World Health Organization (WHO) criteria, 19 namely, serum glucose concentration measured 2 hours after a 75-g oral glucose load following an overnight fast. Fasting serum glucose and insulin concentrations were defined as concentrations of either measure taken after an overnight fast in accordance with the ADA and WHO criteria. HOMA measurements of insulin resistance were required to follow either the original HOMA-IR formula 20 A small proportion of articles included patients with a limited duration of antipsychotic use (2 weeks maximum). In these cases, authors were contacted to obtain access to data concerning patients who were drug naive. If these data were not available, sensitivity analyses were performed examining only studies of patients who had no antipsychotic exposure.
WHO identifies obesity as the strongest risk factor for type 2 diabetes from evidence based on studies across 188 countries. 22 In view of this observation, sensitivity analyses were performed examining studies in which patients and controls were matched on body mass index (BMI) to determine whether failure to match BMI influenced results. The matching was confirmed by either review of study methods or by confirmation of no significant difference between mean BMI levels of the patient and control groups (a 2-tailed P value <.05 was deemed significant). WHO recognizes several other risk factors for type 2 diabetes relating to BMI, including unhealthy diet and physical inactivity. 22 Individuals with schizophrenia engage in significantly less physical exercise than controls, with even lower levels of physical activity observed in early stages of the illness. 23 In addition, the prodrome is associated with decreased physical activity and poor eating habits. 24, 25 To address whether differences in diet and exercise between patient and control groups influenced the results, sensitivity analyses examining groups matched for diet and exercise were performed. Diet and exercise matching was confirmed either by review of study methods or by confirmation of no significant difference between mean diet and exercise parameters of the patient and control groups (a 2-tailed P value <.05 was deemed significant). Nonmodifiable risk factors for type 2 diabetes, such as ethnicity, are also recognized, 22 and in this context, sensitivity analyses were also performed examining studies in which participants were matched for ethnic background.
Recorded Variables
For every study, data were extracted according to the following model: author, year of publication, country, design (ie, prospective, cross-sectional, case-control, and retrospective), matching criteria for patients and controls (confirmed by review of study methods or by confirmation of nonsignificance between mean parameter levels of patient and control groups; a 2-tailed P value <.05 was deemed significant), whether or not patient groups were antipsychotic naive (and if not, duration of treatment), and mean (SD) measure of glucose homeostasis in patient and control groups. If there were multiple publications for the same data set, data were extracted from the study with the largest data set. The Table demonstrates this data extraction with the exception of raw glucose homeostasis measurements (mean and SDs) , which are documented in eTables 3-7 in the Supplement. The parameters of glucose homeostasis available in the studies described in the Table but not included in meta-analysis, along with the rationale behind exclusion, are documented in the eAppendix in the Supplement.
Statistical Analysis
A 2-tailed P < .05 was deemed significant. A random-effects model was used in all analyses owing to an expectation of heterogeneity of data across studies. Standardized mean differences in glucose homeostasis measurements between patient and control cohorts were used as the effect size, determined using Hedges adjusted g. The 95% CI of the effect size was also calculated. 
Results
Retrieved Studies
After exclusion of studies reporting on overlapping data sets, 16 case-control studies [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] comprising 15 samples met inclusion criteria and were analyzed. The search process is demonstrated in Figure 1 , and the final studies selected are summarized in the Table. The overall sample included 731 patients and 614 controls.
Fasting Plasma Glucose Concentration
Fasting plasma glucose concentration in patients and controls was analyzed using data from 14 studies comprising 718 patients and 599 controls. [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Fasting plasma glucose concentration was significantly elevated in patients compared with controls (Hedges g = 0.20; 95% CI, 0.02 to 0.38; P = .03) ( Figure 2 ). There was significant between-sample heterogeneity, with an I 2 value of 58.29% (Cochran Q = 31.17; P = .003). Findings of the Egger test (P = .07) suggested that publication bias was not significant. Restricting the analyses to antipsychotic-naive patients by excluding the 3 studies that included patients with up to 2 weeks of antipsychotic treatment [37] [38] [39] demonstrated that fasting plasma glucose con-cose concentration remained significantly elevated in patients compared with controls (Hedges g = 0.25; 95% CI, 0.07 to 0.43; P = .007) (eFigure 6 in the Supplement). However, after restricting the analyses to BMI-matched studies, [26] [27] [28] [29] [30] [31] [32] [33] [37] [38] [39] there was no longer a significant difference in fasting plasma glucose concentration in patients compared with controls (Hedges g = 0.20; 95% CI, −0.03 to 0.44; P = .08). A sensitivity analysis examining studies in which patients and controls were matched for ethnicity 26, 31, 34, 36, 37, 39 demonstrated that fasting plasma glucose concentration remained significantly elevated in patients compared with controls (Hedges g = 0.19; 95% CI, 0.03 to 0.35; P = .02).
Plasma Glucose Concentration After OGTT
Plasma glucose concentration after OGTT was analyzed using data from 4 studies comprising 271 patients and 237 controls. [34] [35] [36] [37] Plasma glucose concentration was significantly elevated in patients compared with controls (Hedges g = 0.61; 95% CI, 0.16-1.05; P = .007) (Figure 2 ). Between-sample heterogeneity was significant, with an I 2 value of 82.40% (Cochran Q = 17.05; P = .001). A sensitivity analysis examining studies in which patients and controls were matched for ethnicity 34, 36, 37 demonstrated that fasting plasma glucose concentration after OGTT remained significantly elevated in patients compared with controls (Hedges g = 0.78; 95% CI, 0.40-1.17; P < .001). In the context of low study numbers, sensitivity analyses to assess the impact of BMI, antipsychotics, or diet and exercise were not performed.
Fasting Plasma Insulin Concentration
Fasting plasma insulin concentration in patients and controls was analyzed using data from 11 studies 26, 28, [30] [31] [32] [33] [34] [37] [38] [39] [40] comprising 512 patients and 448 controls. Fasting plasma insulin concentration was significantly raised in patients compared with controls (Hedges g = 0.41; 95% CI, 0.09-0.72; P = .01) ( Figure 3 ). Between-sample heterogeneity was significant, with an I 2 value of 80.80% (Cochran Q = 52.09; P < .001). Find- ings of the Egger test (P = .12) suggested that publication bias was not significant. Excluding the 3 studies that included patients with up to 2 weeks of antipsychotic treatment [37] [38] [39] to restrict the analyses to antipsychotic-naive patients demonstrated that fasting plasma insulin concentration remained significantly elevated in patients compared with controls (Hedges g = 0.47; 95% CI, 0.03-0.91; P = .04). Exclusion of 1 study that examined non-BMI-matched patients and controls 34 demonstrated that fasting plasma insulin concentration remained significantly elevated in patients compared with controls (Hedges g = 0.38; 95% CI, 0.04-0.72; P = .03). A sensitivity analysis examining studies in which patients and controls were matched for ethnicity 26, 31, 34, 37, 46 demonstrated that fasting insulin concentration remained significantly elevated in patients compared with controls (Hedges g = 0.49; 95% CI, 0.30-0.68; P < .001). In the context of low study numbers, a sensitivity analysis to assess the impact of diet and exercise was not performed.
Insulin Resistance
Insulin resistance as measured using the HOMA-IR tool in patients and controls was analyzed using data from 10 studies 26,28-32,34,38,39,41 comprising 485 patients and 400 controls. HOMA-IR was significantly raised in patients compared with controls (Hedges g = 0.35; 95% CI, 0.14-0.55; P = .001) ( Figure 3 ). Between-sample heterogeneity was moderate but significant, with an that HOMA-IR remained significantly elevated in patients compared with controls (Hedges g = 0.31; 95% CI, 0.09-0.53; P = .005). A sensitivity analysis examining studies in which patients and controls were matched for ethnicity 26, 31, 34, 39 demonstrated that HOMA-IR remained significantly elevated in patients compared with controls (Hedges g = 0.66; 95% CI, 0.43-0.88; P < .001). In the context of low study numbers, a sensitivity analysis to assess the impact of diet and exercise was not performed.
HbA 1c Analysis
The HbA 1c levels were analyzed using data from 4 studies 27,34,38,41 comprising 166 patients and 164 controls.
The HbA 1c levels were not altered in patients compared with controls (Hedges g = −0.08; 95% CI, −0.34 to 0.18; P = .55) (eFigure 7 in the Supplement). Between-sample heterogeneity was moderate as indicated by an I 2 value of 31.50%, but a Cochran Q value of 4.38 (P = .22) suggested nonsignificant heterogeneity. Of these 4 studies, 2 studies examined patients with up to 2 weeks of antipsychotic use, 38,41 and 1 study examined non-BMI-matched patients and controls. 34 In the context of low study numbers, sensitivity analyses were not performed.
Discussion
Our main findings are that patients with schizophrenia show raised fasting plasma glucose levels, reduced glucose tolerance, raised fasting plasma insulin levels, and increased insulin resistance at illness onset. With the exception of fasting glucose levels, these alterations were also seen when analyses were restricted to antipsychotic-naive and BMI-matched samples. When analysis was restricted to diet and exercise-matched samples, significance was maintained for raised fasting glucose levels in patients. All results remained significant when analyses were restricted to samples matched for race/ ethnicity. No significant differences were demonstrated in HbA 1c levels, although this result should be interpreted with caution owing to the small sample size used in this analysis.
The results of our meta-analysis extend recent studies showing high rates of diabetes in patients with chronic schizophrenia by demonstrating that altered glucose homeostasis is present from illness onset.
Strengths and Limitations
By focusing our analysis on patients with first-episode schizophrenia, an attempt was made to limit the duration of secondary illness-related factors known to affect glucose homeostasis. However, individuals in the prodromal state and those with first-episode schizophrenia already have poorer dietary habits, decreased physical activity, and an increased likelihood of smoking compared with age-matched controls. [23] [24] [25] 47 Our search did not find any studies that examined glucose homeostasis in individuals at risk for developing psychosis that matched our inclusion criteria, and the duration of untreated psychosis was documented in only 5 of the 16 studies analyzed. 27, 28, 32, 36, 38 Since our definition of first-episode schizophrenia was broad, ranging from first clinical contact to duration of illness up to 5 years following illness onset, 17 quantification of the duration of poor lifestyle habits for the overall sample was not possible, and the small number of studies that specifically documented duration of untreated illness prevented a meta-regression from examining the influence of chronicity of illness on glucose homeostasis. Although a sensitivity analysis examining studies in which participants were matched for diet and exercise remained significant for raised fasting glucose levels in the patient cohort, there was no significant elevation in the BMI-matched sensitivity analysis. However, the sensitivity analyses of fasting insulin levels and insulin resistance showed significant dysregulation for these variables in the patient cohort that was matched by BMI to controls. Thus, although it is a limitation that we were not able to examine their potential influences in all instances, when we were able to examine them, differences in BMI, diet, and exercise did not account for our findings with the exception of BMI for fasting glucose levels.
Although all participants used in the meta-analysis were described as physically healthy with no illnesses that would affect glucose homeostasis, only 8 studies defined use of overthe-counter and prescription medication as a specific exclusion criterion, [28] [29] [30] [31] 34, 36, 37, 41 and only 4 studies defined psychotropic use other than antipsychotics as an exclusion criterion 29, 30, 32, 33 (full details in eTable 8 in the Supplement).
Thus, the potential use of medication other than antipsychotics that might disturb glucose homeostasis is a possible confounding factor in our meta-analysis. We also acknowledge that 4 of the 16 studies used in this meta-analysis analyzed patients with schizophrenia as well as individuals with schizophreniform disorder, brief psychotic disorder, and psychosis not otherwise specified, 27, 37, 38, 41 which may contribute to heterogeneity in the sample. There was also variability in matching criteria for patients and controls, which might be significant given the effect of demographic variables on risk for type 2 diabetes. 22 Nevertheless, 8 studies documented that participants were matched for race/ethnicity, 26, 31, 34, [36] [37] [38] [39] 41 and our sensitivity analyses suggest that differences in ethnicities between groups were not responsible for the overarching findings of the meta-analysis. Two studies failed to match for sex, 28 ,33 1 study failed to match for age, 30 and only 8 studies documented that participants were matched for smoking status [26] [27] [28] 31, 33, 34, 39, 41 (Table and eTable Significant elevation in fasting glucose concentration (Hedges g = 0.20; 95% CI, 0.02-0.38; P = .03) and glucose concentration after OGTT (Hedges g=0.61; 96% CI, 0.16-1.05; P = .007) in patients. Each square shows the effect size for a single study, with the horizontal line running through each square illustrating the width of the 95% CI. The size of the squares reflects the weight attributed to each study. Diamonds illustrate the summary effect sizes, the middle of each diamond represents the summary effect size, and the width of the diamond depicts the width of the overall 95% CI.
tested, including the use of either the original HOMA-IR equation 20 or the HOMA2 equation. 21 Nevertheless, the random-effects model that we used is robust to heterogeneity, and the fact that findings were consistent across different methods suggests that they are robust to technical variation. In view of the findings of our meta-analysis, prospective studies investigating the effect of lifestyle factors on the glucose dysregulation seen in patients with first-episode schizophrenia would help to determine the degree to which alterations are intrinsic to schizophrenia or the consequences of emerging symptoms. Longitudinal studies examining the efficacy of early interventions targeting a reduction in diabetic risk (both lifestyle based and pharmacologic) in individuals with schizophrenia who exhibit subtle early aberrances in glucose homeostasis would be useful.
Although the findings of this meta-analysis may in part reflect poorer lifestyle habits in patients compared with controls, other mechanisms may also contribute to the link between schizophrenia and altered glucose regulation. Both schizophrenia and type 2 diabetes are associated with early developmental risk factors, such as low birth weight, preterm birth, gestational diabetes, and maternal malnutrition or obesity. Significant elevation in fasting insulin concentration (Hedges g = 0.41; 95% CI, 0.09-0.72; P = .01) and HOMA-IR (Hedges g = 0.35; 95% CI, 0.14-0.55; P = .001) in patients. Each square shows the effect size for a single study, with the horizontal line running through each square illustrating the width of the 95% CI. The size of the squares reflects the weight attributed to each study. Diamonds illustrate the summary effect sizes, the middle of each diamond represents the summary effect size, and the width of the diamond depicts the width of the overall 95% CI. n/a Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
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Reporting of methods should include
Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested Detailed inclusion and exclusion criteria are described in the paper.
Rationale for the selection and coding of data A data extraction sheet was developed (available on request). Data on study characteristics, methodological quality and results were independently extracted from each selected article.
Assessment of confounding
We conducted sub-group analyses examining studies where participants were BMI matched, and studies where patients were totally drug naïve. Assessment of study quality Study quality was assessed using the Newcastle-Ottowa Scale, and bias assessed using Egger's test of the intercept and represented diagrammatically with Funnel Plots.
Assessment of heterogeneity
The I 2 value was used to assess heterogeneity. Description of statistical methods in sufficient detail to be replicated
We mentioned the type of analysis we used, and the type of software utilised. Raw data is presented in the appendix.
Provision of appropriate tables and graphics
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